Exploring patients' perceptions for insulin therapy in type 2 diabetes: A Brazilian and Canadian qualitative study

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 171-179

  Guimarães, Camila ^b   Marra, Carlo A ^a   Gill, Sabrina ^a   Meneilly, Graydon ^a   Simpson, Scot ^c   Godoy, Ana L P C ^b   de Freitas, Maria Cristina Foss ^b   Queiroz, Regina H C ^b   Lynd, Larry ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Glycemic control; Hypoglycemia; Insulin administration; Patients' preferences; Qualitative study; Type 2 diabetes; Weight gain

Indexed keywords

EID: 77954614856     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/ppa.s10178     Document Type: Article

References (35)

1. Public Health Agency of Canada. Diabetes in Canada, 2nd edn., Ottawa, Canada: Public Health Agency of Canada; 2002.
2. Ohinmaa A, Jacobs P, Simpson S, Johnson JA. The projection of prevalence and cost of diabetes in Canada: 2000 to 2016. Canadian Journal of Diabetes. 2004;28(2):116-123.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
4. Idf.org. [homepage on the internet]. International Diabetes Federation. Diabetes Atlas: Executive Summary. 2003, Second edn. Available from http://www.idf.org/e-atlas. Accessed September 15, 2006.
5. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(3):S18-24.
7. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-246.
8. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28: 2673-2679.
9. Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care. 2000; 23:1799-1803.
10. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-2545.
11. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther. 2002;4: 459-466.
12. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001; 134:203-207.
13. Hayes RP, Muchmore D, Schmitke J. Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. Curr Med Res Opin. 2007;23:435-442.
14. Bauman AE, Fardy HJ, Harris PG. (2003) Getting it right: why bother with patient-centred care? Med J Aust. 2003;179:253-256.
15. Funnell MM, Anderson RM. MSJAMA: the problem with compliance in diabetes. JAMA. 2000;284:1709.
16. Hayes RP, Bowman L, Monahan PO, et al. Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ. 2006;32:404-414.
17. Kruger DF. Tying it all together: matching insulin regimens to individual patient needs. Diabetes Educ. 2007;33(4):91S-95S.
18. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331-342.
19. Cefalu WT, Chantal M, Davidson J, Freemantle N, Gough S, Canovatchel W. Patients' perceptions of subcutaneous insulin in the OPTIMIZE Study: A multicenter follow-Up study. Diabetes Technol. Ther. 2008; 10:25-38
20. Sadri H, MacKeigan LD, Leiter LA, Einarson TR. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics. 2005;23:1215-1227.
21. Trochim WMK. The Research Methods Knowledge Base, 2nd edn. Cincinnati, Ohio: Atomic Dog Publishers; 2001.
22. Duke SS, Gordon-Sosby K, Reynolds KD, Gram IT. A study of breast cancer detection practices and beliefs in black women attending public health clinics. Health Educ Res. 1994;9:331-342.
23. Kitzinger J. Qualitative research. Introducing focus groups. BMJ. 1995; 311:299-302.
24. Rabiee F. Focus-group interview and data analysis. Proc Nutr Soc. 2004;63:655-660.
25. Kaplowitz MD, Hoehn JP. Do focus groups and individual interviews reveal the same information for natural resource valuation? Ecological Economics. 2001;36:237-247.
26. Giacomini MK, Cook DJ. Users' guides to the medical literature: XXIII. Qualitative research in health care B. What are the results and how do they help me care for my patients? Evidence-Based Medicine Working Group. JAMA. 2000;284:478-482.
27. Krueger R. Focus Groups: A Practical Guide for Applied Research. Thousand Oaks, CA: Sage Publications; 1994.
28. Lewis M. Focus group interviews in qualitative research: A review of the literature. Action Research E-Reports: 2000.
29. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26:1498-1505.
30. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-428.
31. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20:292-298.
32. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:9S-18S.
33. Penckofer S, Ferrans CE, Velsor-Friedrich B, Savoy S. The psychological impact of living with diabetes: women's day-to-day experiences. Diabetes Educ. 2007;33:680-690.
34. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848.
35. Nih.gov [homepage on the internet]. National Institutes of Health. For Safety, NHLBI Changes Intensive Boold Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease. U.S Department of Health and Human Services - National institutes of Health (NIH) Available from: www.nih.gov/news/health/feb2008/nhlbi-06.htm). Accessed February 26, 2008.